drugset / Trial / NCT05495100
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma
Phase 2
Unknown
45 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Huizhou Municipal Central Hospital · collabJinhua Central Hospital · collabNingbo No. 1 Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with chidamide and azacitidine in the treatment of relapsed and refractory peripheral T-cell lymphoma
Timeline
- Start
- 2022-08-11
- Primary completion
- 2023-08-11
- Completion
- 2024-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |